Epigenetic Silencing of Immune-Checkpoint Receptors in Bone Marrow- Infiltrating T Cells in Acute Myeloid Leukemia

BACKGROUND: Immune-checkpoint (IC) inhibitors have revolutionized the treatment of multiple solid tumors and defined lymphomas, but they are largely ineffective in acute myeloid leukemia (AML). The reason why especially PD1/PD-L1 blocking agents are not efficacious is not well-understood but it may...

Descripción completa

Detalles Bibliográficos
Autores principales: Radpour, Ramin, Stucki, Miriam, Riether, Carsten, Ochsenbein, Adrian F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130556/
https://www.ncbi.nlm.nih.gov/pubmed/34017684
http://dx.doi.org/10.3389/fonc.2021.663406

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130556/
https://www.ncbi.nlm.nih.gov/pubmed/34017684
http://dx.doi.org/10.3389/fonc.2021.663406

Ejemplares similares